TriSalus Life Sciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $45.2M | $29.4M | $18.5M | $12.4M | — |
| Gross profit | $38.2M | $25.3M | $15.9M | $10.1M | — |
| Operating income | -$26.9M | -$36.2M | -$54.5M | -$36.4M | -$3.0M |
| Cost of revenue | $7.0M | $4.1M | $2.6M | $2.3M | — |
| Cash from operations | -$18.0M | -$40.8M | -$50.6M | -$32.3M | -$1.7M |
| Capital expenditure | $918,000 | $345,000 | $588,000 | $655,000 | — |
| Free cash flow | -$18.9M | -$41.2M | -$51.2M | -$33.0M | — |
| Share repurchases | — | — | — | $232.4M | — |
| Total assets | $35.3M | $24.0M | $24.6M | $22.0M | $250.5M |
| Total liabilities | $69.2M | $49.9M | $51.7M | $34.3M | $17.3M |
Shares outstanding 61.4M · Free float 55.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.